美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Ohr Pharmaceutical Inc.

5.39

0.0000

成交量：- -

成交額：- -

市值：1,524.96萬

市盈率：-1.70

高：5.39

開：5.39

低：5.39

收：5.39

52周最高：6.28

52周最低：1.58

股本：282.92萬

流通股本：244.59萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-3.1637

每股收益(LYR):-4.6939

淨資產收益率：-67.07%

總資產收益率：-18.45%

市淨率：1.69

市盈率(LYR):-1.15

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Ohr Pharmaceutical Inc.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.ohrpharmaceutical.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Ohr Pharmaceutical, Inc.2009年8月4日在特拉華州註冊，Ohr Pharmaceutical, Inc.是一家製藥公司，專註於新型療法和交付技術的發展為眼部疾病的治療。公司發展管道在不同的發展階段由多個發展計劃和指示。公司鉛臨床方案，OHR-102眼藥水，是一種新的治療產品，其可以提供一種非侵入性的治療，改善視力預后，而不需要每個辦公室訪問多次注射。公司正在評估OHR-102滴眼液，在給定的組合使用Lucentis注射，在多個相的視網膜疾病的治療中，包括濕的AMD，視網膜靜脈阻塞症，增殖性糖尿病性視網膜病和糖尿病性黃斑水腫II期研究。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/OHRP/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OHRP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OHRP\",,,,,undefined,":{"symbol":"OHRP","market":"US","secType":"STK","nameCN":"Ohr Pharmaceutical Inc.","latestPrice":5.39,"timestamp":1562961599999,"preClose":5.39,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":2445876,"shares":2829248,"eps":-3.163664,"marketStatus":"未開盤","change":0,"latestTime":"07-12 15:59:59 EDT","open":5.39,"high":5.39,"low":5.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.163664,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1772096400000},"marketStatusCode":0,"symbolChange":{"newSymbol":"NBSE","executeDate":"2019-07-15"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.39,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OHRP\",,,,,undefined,":{"symbol":"OHRP","floatShares":2445876,"roa":"-18.45%","roe":"-67.07%","lyrEps":-4.693947,"shares":2829248,"dividePrice":0,"high":5.39,"amplitude":0,"preClose":5.39,"low":5.39,"week52Low":1.582,"pbRate":"1.69","week52High":6.28,"institutionHeld":0,"latestPrice":5.39,"eps":-3.163664,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.163664,"open":5.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OHRP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-07-15","symbol":"OHRP","oldSymbol":"OHRP","newSymbol":"NBSE","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1563163200000},{"market":"US","date":"2019-05-15","symbol":"OHRP","fiscalQuarterEnding":"2019/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1557892800000,"reportTimeType":"","actualEps":-0.4},{"date":"2019-02-04","symbol":"OHRP","type":"split","dateTimestamp":1549256400000,"forFactor":20,"toFactor":1},{"market":"US","date":"2018-08-14","symbol":"OHRP","name":"Ohr Pharmaceutical Inc.","time":"","type":"earning","dateTimestamp":1534219200000,"reportTimeType":"","actualEps":-0.01},{"market":"US","date":"2018-05-15","symbol":"OHRP","name":"Ohr Pharmaceutical Inc.","time":"","type":"earning","dateTimestamp":1526356800000,"reportTimeType":"","actualEps":-0.05}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OHRP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OHRP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.ohrpharmaceutical.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Ohr Pharmaceutical, Inc.2009年8月4日在特拉華州註冊，Ohr Pharmaceutical, Inc.是一家製藥公司，專註於新型療法和交付技術的發展為眼部疾病的治療。公司發展管道在不同的發展階段由多個發展計劃和指示。公司鉛臨床方案，OHR-102眼藥水，是一種新的治療產品，其可以提供一種非侵入性的治療，改善視力預后，而不需要每個辦公室訪問多次注射。公司正在評估OHR-102滴眼液，在給定的組合使用Lucentis注射，在多個相的視網膜疾病的治療中，包括濕的AMD，視網膜靜脈阻塞症，增殖性糖尿病性視網膜病和糖尿病性黃斑水腫II期研究。","exchange":"NASDAQ","name":"Ohr Pharmaceutical Inc.","nameEN":"Ohr Pharmaceutical"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OHRP\",market:\"US\",,,undefined,":null}}